4.8 Article

CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment

Journal

CELL
Volume 184, Issue 17, Pages 4512-+

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2021.07.015

Keywords

-

Funding

  1. Harvard Medical School Foundry award
  2. National Institutes of Health (NIH) [P01-CA240239, R01 AI084880, R01 CA218579, R01 AI123349, R01 CA206890, R01 CA204028, R01 AI134713, R21AI142667]
  3. BMBF project Oncoattract
  4. MSC network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union [955575]
  5. Bavarian Ministry for Economic Affairs (CARMOUFLAGE)
  6. ERC grant [756017]
  7. i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
  8. Melanoma Research Alliance Established Investigator Award [827872]
  9. Melanoma Research Foundation
  10. ISREC Foundation
  11. EMBO fellowship [ALTF534-2015]
  12. Marie Curie Global Fellowship [750973]
  13. DFG [PR 1652/1-1, PR 1652/2-1]
  14. German Academic Scholarship Foundation
  15. LMU Prosa Scholarship
  16. Swiss National Science Foundation Early Postdoctoral Mobility Award [P3BEP3_165406]
  17. American Association for Cancer Research Basic Science Fellowship Program [18-4001-OZGA]
  18. Bloomberg Philanthropies
  19. Marie Curie Actions (MSCA) [955575, 750973] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

The conversion of stem-like CTLs into effector-like CTLs involves chemotactic reprogramming with upregulation of chemokine receptor CXCR6. CXCR6 expression and IL-15 trans-presentation are crucial for the survival and local expansion of effector-like CTLs in the tumor microenvironment.
Cytotoxic T lymphocyte (CTL) responses against tumors are maintained by stem-like memory cells that selfrenew but also give rise to effector-like cells. The latter gradually lose their anti-tumor activity and acquire an epigenetically fixed, hypofunctional state, leading to tumor tolerance. Here, we show that the conversion of stem-like into effector-like CTLs involves a major chemotactic reprogramming that includes the upregulation of chemokine receptor CXCR6. This receptor positions effector-like CTLs in a discrete perivascular niche of the tumor stroma that is densely occupied by CCR7(+) dendritic cells (DCs) expressing the CXCR6 ligand CXCL16. CCR7(+) DCs also express and trans-present the survival cytokine interleukin-15 (IL-15). CXCR6 expression and IL-15 trans-presentation are critical for the survival and local expansion of effector-like CTLs in the tumor microenvironment to maximize their anti-tumor activity before progressing to irreversible dysfunction. These observations reveal a cellular and molecular checkpoint that determines the magnitude and outcome of anti-tumor immune responses.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available